Can you please share the source of this document you refer to?
Posts in category Value Pickr
Piramal Enterprises Ltd (31-08-2022)
I think you might have got it right. Another aspect is time of acquisition for calculation of capital gain/loss. As you mention you holding it since 5 years, will acquisition time for Pharma shares be when u acquired the original shares of whole business or when this subsidiary was incubated within Piramal (say if it was incubated 3 years back only just for sake of example & learning) or the date of credit of Pharma shares to your dmat account?
Prior to its listing or credit to dmat account date, the scrip ID would not even exist and so to have it’s acquisition date prior to that can be technically incorrect in case someone has to report details for tax purposes…thought welcome
Ramana’s Portfolio – Feedback most welcome! (31-08-2022)
True. My self observed lot of HNIs having more than 50+ shares in their portfolio, few i saw 100 where there networth is more than 400cr+, myself when in learning phase had 60 stocks and had 100% profit in 3 yrs including 3stocka with 70%+loss, i think everyone should follow their own style investment and intelligence with patience and controlled emotiona for sure market works for all that don’t make bias until we are patient and less emotional
How to register with SEBI as a Research Analyst? (31-08-2022)
Things are getting funny with my application. Previously my application was showing approved but now it changed to under process again.
Demergers on the radar (31-08-2022)
No you will not get it. Settlement cycle (T+2) needed you to own PEL stocks on or before 29th August to get Piramal pharma.
Demergers on the radar (31-08-2022)
For the purpose of issuing and allocating 4 equity shares of Piramal Pharma (PPL) worth Rs10 each for every equity share worth Rs2 granted to PEL shareholders, the record date is set as September 1, 2022.
Piramal’s financial business contributed about 52 per cent of revenue of the company in the financial year 2021-22, whereas the remaining 48 per cent of revenue came from the pharmaceutical business.
In July this year, PEL said it had also received RBI approval for the NBFC licence. Subsequent to the demerger, PEL said as an NBFC it will have a loan book of $9 billion, while the pharma firm will be a significant player with revenues of $1 billion.